Melanie Shapiro laboratory

Genetics of Type 1 Diabetes Development and Immunotherapy Response

Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy


Journal article


Matthew E Brown, Leeana D. Peters, Seif R. Hanbali, Juan M. Arnoletti, Lindsey K. Sachs, Kayla Q. Nguyen, Emma B. Carpenter, Howard R. Seay, C. Fuhrman, A. Posgai, Melanie R. Shapiro, T. Brusko
Frontiers in Immunology, 2022

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Brown, M. E., Peters, L. D., Hanbali, S. R., Arnoletti, J. M., Sachs, L. K., Nguyen, K. Q., … Brusko, T. (2022). Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy. Frontiers in Immunology.


Chicago/Turabian   Click to copy
Brown, Matthew E, Leeana D. Peters, Seif R. Hanbali, Juan M. Arnoletti, Lindsey K. Sachs, Kayla Q. Nguyen, Emma B. Carpenter, et al. “Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy.” Frontiers in Immunology (2022).


MLA   Click to copy
Brown, Matthew E., et al. “Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy.” Frontiers in Immunology, 2022.


BibTeX   Click to copy

@article{matthew2022a,
  title = {Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy},
  year = {2022},
  journal = {Frontiers in Immunology},
  author = {Brown, Matthew E and Peters, Leeana D. and Hanbali, Seif R. and Arnoletti, Juan M. and Sachs, Lindsey K. and Nguyen, Kayla Q. and Carpenter, Emma B. and Seay, Howard R. and Fuhrman, C. and Posgai, A. and Shapiro, Melanie R. and Brusko, T.}
}

Abstract

Regulatory T cell (Treg) adoptive cell therapy (ACT) represents an emerging strategy for restoring immune tolerance in autoimmune diseases. Tregs are commonly purified using a CD4+CD25+CD127lo/- gating strategy, which yields a mixed population: 1) cells expressing the transcription factors, FOXP3 and Helios, that canonically define lineage stable thymic Tregs and 2) unstable FOXP3+Helios- Tregs. Our prior work identified the autoimmune disease risk-associated locus and costimulatory molecule, CD226, as being highly expressed not only on effector T cells but also, interferon-γ (IFN-γ) producing peripheral Tregs (pTreg). Thus, we sought to determine whether isolating Tregs with a CD4+CD25+CD226- strategy yields a population with increased purity and suppressive capacity relative to CD4+CD25+CD127lo/- cells. After 14d of culture, expanded CD4+CD25+CD226- cells displayed a decreased proportion of pTregs relative to CD4+CD25+CD127lo/- cells, as measured by FOXP3+Helios- expression and the epigenetic signature at the FOXP3 Treg-specific demethylated region (TSDR). Furthermore, CD226- Tregs exhibited decreased production of the effector cytokines, IFN-γ, TNF, and IL-17A, along with increased expression of the immunoregulatory cytokine, TGF-β1. Lastly, CD226- Tregs demonstrated increased in vitro suppressive capacity as compared to their CD127lo/- counterparts. These data suggest that the exclusion of CD226-expressing cells during Treg sorting yields a population with increased purity, lineage stability, and suppressive capabilities, which may benefit Treg ACT for the treatment of autoimmune diseases.


Share

Tools
Translate to